SCHEMBL4430408

SCHEMBL4430408

COCCNC(=O)c1ccccc1C1CCN(CCN2C=COC(C3=CC=CC(=O)C3)=C2)CC1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 3/20 0.37
DRD3 P35462 5/20 0.36
POLB P06746 1/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPK1 P28482 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DRD2 P14416 4/20 0.34
HTR2A P28223 4/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BCL3 P20749 2/20 0.33
GAA P10253 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890241 0.95 HPGD (0.37) UTS2RDRD3ALDH1A1KDM4EHPGD
SCHEMBL4440078 0.92 UTS2R (0.36) UTS2RDRD3DRD2HTR2ABCL3
SCHEMBL4891155 0.92 UTS2R (0.36) UTS2RDRD3BCL3HDAC3HDAC1
SCHEMBL4430165 0.91 HPGD (0.39) UTS2RDRD3POLBALDH1A1KDM4E
SCHEMBL4890309 0.91 BCL3 (0.35) UTS2RDRD3BCL3HDAC3HDAC1
SCHEMBL4885280 0.90 STAT3 (0.37) UTS2RDRD3POLBALDH1A1KDM4E
SCHEMBL4433580 0.90 HDAC3 (0.36) UTS2RPOLBALDH1A1MAPK1KDM4E
SCHEMBL4432781 0.89 NPFFR1 (0.36) UTS2RPOLBALDH1A1KDM4EHPGD
SCHEMBL4881598 0.89 SMN1; SMN2 (0.40) ALDH1A1KDM4EHPGDHSD17B10BCL3
SCHEMBL4890066 0.89 BCL3 (0.38) DRD3POLBALDH1A1HPGDDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US claimed
EP-2049120-A1 UROTENSIN II RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2009-04-22 EP claimed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US claimed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO claimed
EP-2049120-A1 UROTENSIN II RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2009-04-22 EP disclosed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 UTS2R 1/4885DRD3 1857/4885POLB 4040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.